|
1
|
Chang BS and Lowenstein DH: Epilepsy. N
Engl J Med. 349:1257–1266. 2003.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Fisher RS, Acevedo C, Arzimanoglou A,
Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA,
Glynn M, et al: ILAE official report: A practical clinical
definition of epilepsy. Epilepsia. 55:475–482. 2014.PubMed/NCBI View Article : Google Scholar
|
|
3
|
GBD 2015 Disease and Injury Incidence and
Prevalence Collaborators. Global, regional, and national incidence,
prevalence, and years lived with disability for 310 diseases and
injuries, 1990-2015: A systematic analysis for the Global Burden of
Disease Study 2015. Lancet. 388:1545–1602. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kernich CA: Patient and family fact sheet
Epilepsy. Neurologist. 9:265–266. 2003.PubMed/NCBI View Article : Google Scholar
|
|
5
|
GBD 2015 Mortality and Causes of Death
Collaborators. Global, regional, and national life expectancy,
all-cause mortality, and cause-specific mortality for 249 causes of
death, 1980-2015: A systematic analysis for the Global Burden of
Disease Study 2015. Lancet. 388:1459–1544. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
GBD 2013 Mortality and Causes of Death
Collaborators. Global, regional, and national age-sex specific
all-cause and cause-specific mortality for 240 causes of death,
1990-2013: A systematic analysis for the Global Burden of Disease
Study 2013. Lancet. 385:117–171. 2015.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Brodie MJ, Elder AT and Kwan P: Epilepsy
in later life. Lancet Neurol. 8:1019–1030. 2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Eadie MJ: Shortcomings in the current
treatment of epilepsy. Expert Rev Neurother. 12:1419–1427.
2012.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kwan P and Brodie MJ: Early identification
of refractory epilepsy. N Engl J Med. 342:314–319. 2000.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Wei CX, Bian M and Gong GH: Current
research on antiepileptic compounds. Molecules. 20:20741–20776.
2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Suzuki Y, Takahashi H, Fukuda M, Hino H,
Kobayashi K, Tanaka J and Ishii E: β-Hydroxybutyrate alters
GABA-transaminase activity in cultured astrocytes. Brain Res.
1268:17–23. 2009.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Samoilova M, Weisspapir M, Abdelmalik P,
Velumian AA and Carlen PL: Chronic in vitro ketosis is
neuroprotective but not anti-convulsant. J Neurochem. 113:826–835.
2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Maalouf M and Rho JM: Oxidative impairment
of hippocampal long-term potentiation involves activation of
protein phosphatase 2A and is prevented by ketone bodies. J
Neurosci Res. 86:3322–3330. 2008.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Likhodii SS and Burnham WM: Ketogenic
diet: Does acetone stop seizures? Med Sci Monit. 8:HY19–HY24.
2002.PubMed/NCBI
|
|
15
|
Abdelmalik PA, Shannon P, Yiu A, Liang P,
Adamchik Y, Weisspapir M, Samoilova M, Burnham WM and Carlen PL:
Hypoglycemic seizures during transient hypoglycemia exacerbate
hippocampal dysfunction. Neurobiol Dis. 26:646–660. 2007.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Yum MS, Ko TS and Dong WK: Anticonvulsant
effects of β-hydroxybutyrate in mice. J Epilepsy Res. 2:29–32.
2012.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Yum MS, Ko TS and Kim DW:
β-Hydroxybutyrate increases the pilocarpine-induced seizure
threshold in young mice. Brain Dev. 34:181–184. 2012.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Minlebaev M and Khazipov R: Antiepileptic
effects of endogenous beta-hydroxybutyrate in suckling infant rats.
Epilepsy Res. 95:100–109. 2011.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Thio LL, Wong M and Yamada KA: Ketone
bodies do not directly alter excitatory or inhibitory hippocampal
synaptic transmission. Neurology. 54:325–331. 2000.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Si J, Wang S, Liu N, Yang X, Wang Y, Li L,
Wang J and Lv X: Anticonvulsant effect of exogenous
β-hydroxybutyrate on kainic acid-induced epilepsy. Exp Ther Med.
14:765–770. 2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
National Research Council: Guide for the
Care and Use of Laboratory Animals. 8th edition. Washington (DC):
National Academies Press (US); 2011. Available from: urihttps://www.ncbi.nlm.nih.gov/books/NBK54050/simplehttps://www.ncbi.nlm.nih.gov/books/NBK54050/
doi: 10.17226/12910ß.
|
|
22
|
Racine RJ: Modification of seizure
activity by electrical stimulation II Motor seizure.
Electroencephalogr Clin Neurophysiol. 32:281–294. 1972.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Xie G, Tian W, Wei T and Liu F: The
neuroprotective effects of β-hydroxybutyrate on Aβ-injected rat
hippocampus in vivo and in Aβ-treated PC-12 cells in vitro. Free
Radic Res. 49:139–150. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Bindra A, Kaushal A, Prabhakar H,
Chaturvedi A, Chandra PS, Tripathi M, Subbiah V, Sathianathan S,
Banerjee J and Prakash C: Neuroprotective role of dexmedetomidine
in epilepsy surgery: A preliminary study. Neurol India. 67:163–168.
2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Maiti R, Mishra BR, Sanyal S, Mohapatra D,
Parida S and Mishra A: Effect of carbamazepine and oxcarbazepine on
serum neuron-specific enolase in focal seizures: A randomized
controlled trial. Epilepsy Res. 138:5–10. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Yardimoğlu M, Ilbay G, Dalcik C, Dalcik H,
Sahin D and Ates N: Immunocytochemistry of neuron specific enolase
(NSE) in the rat brain after single and repeated epileptic
seizures. Int J Neurosci. 118:981–993. 2008.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Jacque CM, Vinner C, Kujas M, Raoul M,
Racadot J and Baumann NA: Determination of glial fibrillary acidic
protein (GFAP) in human brain tumors. J Neurol Sci. 35:147–155.
1978.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Venkatesh K, Srikanth L, Vengamma B,
Chandrasekhar C, Sanjeevkumar A, Mouleshwara Prasad BC and Sarma
PV: In vitro differentiation of cultured human CD34+ cells into
astrocytes. Neurol India. 61:383–388. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Alese OO and Mabandla MV: Upregulation of
hippocampal synaptophysin, GFAP and mGluR3 in a pilocarpine rat
model of epilepsy with history of prolonged febrile seizure. J Chem
Neuroanat. 100(101659)2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Puttachary S, Sharma S, Stark S and
Thippeswamy T: Seizure-induced oxidative stress in temporal lobe
epilepsy. Biomed Res Int. 2015(745613)2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yuen AWC, Keezer MR and Sander JW:
Epilepsy is a neurological and a systemic disorder. Epilepsy Behav.
78:57–61. 2018.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Pearson-Smith JN and Patel M: Metabolic
dysfunction and oxidative stress in epilepsy. Int J Mol Sci.
18(2365)2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Pompella A, Visvikis A, Paolicchi A, De
Tata V and Casini AF: The changing faces of glutathione, a cellular
protagonist. Biochem Pharmacol. 66:1499–1503. 2003.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Lutchmansingh FK, Hsu JW, Bennett FI,
Badaloo AV, McFarlane-Anderson N, Gordon-Strachan GM, Wright-Pascoe
RA, Jahoor F and Boyne MS: Glutathione metabolism in type 2
diabetes and its relationship with microvascular complications and
glycemia. PLoS One. 13(e0198626)2018.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Sprietsma JE: Cysteine, glutathione (GSH)
and zinc and copper ions together are effective, natural,
intracellular inhibitors of (AIDS) viruses. Med Hypotheses.
52:529–538. 1999.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Guo Q, Liu S, Wang S, Wu M, Li Z and Wang
Y: Beta-hydroxybutyric acid attenuates neuronal damage in
epilepticmice. Acta Histochem. 121:455–459. 2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Bhagat K, Singh JV, Pagare PP, Kumar N,
Sharma A, Kaur G, Kinarivala N, Gandu S, Singh H, Sharma S and Bedi
PMS: Rational approaches for the design of various GABA modulators
and their clinical progression. Mol Divers 2020 (Epub ahead of
print).
|
|
38
|
Treiman DM: GABAergic mechanisms in
epilepsy. Epilepsia. 42 (Suppl 3):S8–S12. 2001.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Cepeda C, Levinson S, Nariai H, Yazon VW,
Tran C, Barry J, Oikonomou KD, Vinters HV, Fallah A, Mathern GW and
Wu JY: Pathological high frequency oscillations associate with
increased GABA synaptic activity in pediatric epilepsy surgery
patients. Neurobiol Dis. 134(104618)2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Simeone TA, Simeone KA and Rho JM: Ketone
bodies as anti-seizure agents. Neurochem Res. 42:2011–2018.
2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Li J, O'Leary EI and Tanner GR: The
ketogenic diet metabolite beta-hydroxybutyrate (β-HB) reduces
incidence of seizure-like activity (SLA) in a Katp- and
GABAb-dependent manner in a whole-animal Drosophila melanogaster
model. Epilepsy Res. 133:6–9. 2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Mejía-Toiber J, Montiel T and Massieu L:
D-beta-hydroxybutyrate prevents glutamate-mediated lipoperoxidation
and neuronal damage elicited during glycolysis inhibition in vivo.
Neurochem Res. 31:1399–1408. 2006.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Mudaliar S, Alloju S and Henry RR: Can a
shift in fuel energetics explain the beneficial cardiorenal
out-comes in the EMPA-REG OUTCOME study? A unifying hypothesis.
Diabetes Care. 39:1115–1122. 2016.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Lund TM, Ploug KB, Iversen A, Jensen AA
and Jansen-Olesen I: The metabolic impact of β-hydroxybutyrate on
neurotransmission: Reduced glycolysis mediates changes in calcium
responses and KATP channel receptor sensitivity. J Neurochem.
132:520–531. 2015.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Tanner G, Lutas A, Martínez-François JR
and Yellen G: Single K ATP channel opening in response to action
potential firing in mouse dentate granule neurons. J Neurosci.
31:8689–8696. 2011.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Giménez-Cassina A, Martínez-François JR,
Fisher JK, Szlyk B, Polak K, Wiwczar J, Tanner GR, Lutas A, Yellen
G and Danial NN: BAD-dependent regulation of fuel metabolism and
K(ATP) channel activity confers resistance to epileptic seizures.
Neuron. 74:719–730. 2012.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Soto-Mota A, Norwitz NG and Clarke K: Why
a d-β-hydroxybutyrate monoester? Biochem Soc Trans. 48:51–59.
2020.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Krishnan M, Hwang JS, Kim M, Kim YJ, Seo
JH, Jung J and Ha E: β-hydroxybutyrate impedes the progression of
Alzheimer's disease and atherosclerosis in ApoE-deficient mice.
Nutrients. 12(471)2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Norwitz NG, Hu MT and Clarke K: The
mechanisms by which the ketone body D-β-hydroxybutyrate may improve
the multiple cellular pathologies of Parkinson's disease. Front
Nutr. 6(63)2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Yum MS, Lee M, Woo DC, Kim DW, Ko TS and
Velíšek L: β-Hydroxybutyrate attenuates NMDA-induced spasms in rats
with evidence of neuronal stabilization on MR spectroscopy.
Epilepsy Res. 117:125–132. 2015.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Giordano C, Marchiò M, Timofeeva E and
Biagini G: Neuroactive peptides as putative mediators of
antiepileptic ketogenic diets. Front Neurol. 5(63)2014.PubMed/NCBI View Article : Google Scholar
|
